Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC

NCT03564197 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT03564197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03564197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC
Lead sponsor
The Netherlands Cancer Institute
Phase
Not applicable
Overall status
Completed
Start date
October 25, 2018
Completion date
January 30, 2026
Enrollment
80 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv